Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Rheumatology
Published in: Pediatric Rheumatology 1/2013

Open Access 01-11-2013 | Meeting abstract

PW02-041 - Canakinumab treatment regimens in CAPS-patients

Authors: F Hofer, T Endres, B Kortus-Götze, N Blank, E Weißbarth-Riedel, C Schuetz, T Kallinich, K Krause, C Rietschel, G Horneff, J Kuemmerle-Deschner

Published in: Pediatric Rheumatology | Special Issue 1/2013

Login to get access

Excerpt

Canakinumab is a recombinant monoclonal fully human antibody against Interleukin-1β and currently the only drug approved for the treatment of CAPS in Europe. Current dose recommendations are 150mg (body weight >40kg) respectively 2mg/kg bodyweight (15 to 40kg) every 8 weeks but yield insufficient response in some individuals, especially in children and patients with severe phenotypes [1]. …
Literature
1.
Kuemmerle-Deschner JB: Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study. Ann Rheum Dis. 2011, 70: 2095-2102.CrossRefPubMed
Metadata
Title
PW02-041 - Canakinumab treatment regimens in CAPS-patients
Authors
F Hofer
T Endres
B Kortus-Götze
N Blank
E Weißbarth-Riedel
C Schuetz
T Kallinich
K Krause
C Rietschel
G Horneff
J Kuemmerle-Deschner
Publication date
01-11-2013
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue Special Issue 1/2013
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/1546-0096-11-S1-A182

Other articles of this Special Issue 1/2013

Pediatric Rheumatology 1/2013 Go to the issue

Meeting abstract

PW02-011 - Favorable response to anakinra in aisle patients

Meeting abstract

P03-012 - A P268S NOD2 mutation in one Blau patient

Meeting abstract

P03-015 - Dapson treats chronic Pupura Schoenlein (PSH)

Meeting abstract

OR3-002 – Blau Syndrome cohort study: ocular outcome

Meeting abstract

PW03-023 – Role of S100A4 in inflammatory disorders

Meeting abstract

P03-017 - Health related quality of life in adult with HRFS